View of Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025)

Return to Article Details Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025) Download Download PDF